Trial reportCancer immunology, immunotherapy : CII2026
A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma.
Trial report in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05235074 (A Clinical Study of Oncolytic Virus), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Study of Oncolytic Virus (OH2) Injection in the Treatment of Patients Undergoing Surgery After Recurrence of Central Nervous System Tumors
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundGlioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor with limited survival despite multimodal therapy. Its profoundly immunosuppressive tumor microenvironment severely restricts treatment efficacy. Oncolytic viruses represent a promising therapeutic strategy, yet the immunological mechanisms underlying the antitumor activity of OH2 (oncolytic herpes simplex virus type 2) remain poorly defined.
methodsThe effects of OH2 were evaluated in GBM cell lines (U251, LN229 and GL261) by assessing cell viability, migration, apoptosis, and cell cycle distribution. Modulation of tumor-associated macrophages (TAMs) was examined in RAW264.7 and THP-1 cells through functional assays, RNA sequencing, Western blotting and pharmacologic inhibition. In vivo studies were performed in subcutaneous and orthotopic GBM models to assess tumor growth and immune alterations. Exploratory clinical observations were conducted in seven recurrent GBM patients (NCT05235074), including peripheral blood monocyte profiling, longitudinal immune monitoring and cytokine analysis.
resultsOH2 induced apoptotic and oncolytic cell death in GBM cells, while inhibiting cell proliferation and migration in vitro. In macrophage models, exposure to OH2-conditioned media enhanced proliferation and phagocytic activity and promoted M1-like polarization, accompanied by activation of JAK-STAT1 signaling. In vivo, OH2 suppressed tumor growth, promoted M1-like TAM polarization, reduced immunosuppressive macrophage populations, and increased recruitment of bone marrow-derived macrophages into the brain. Exploratory clinical observation suggested that changes in peripheral monocyte profiles may be associated with clinical benefit.
conclusionsOH2 exerts antitumor activity in GBM through direct oncolysis and immune microenvironment modulation, highlighting its potential as an immunotherapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.